Summary
Pfizer Inc. (PFE) has filed a Current Report on Form 8-K detailing a significant development in a shareholder derivative lawsuit. On December 14, 2010, the U.S. District Court for the Southern District of New York granted preliminary approval for a proposed settlement in the case, In re Pfizer Inc. Shareholder Derivative Litigation. This approval is a crucial step towards resolving the litigation that has been previously disclosed in Pfizer's SEC filings. The proposed settlement is contingent upon final court approval, which is scheduled to be determined at a hearing on March 7, 2011. The specifics of the settlement terms are outlined in the "Notice of Pendency and Proposed Settlement of Shareholder Derivative Litigation" dated December 14, 2010, which has been filed as an exhibit to this report. Investors should monitor the outcome of the final approval hearing to understand the full implications of this settlement on the company.
Key Highlights
- 1Pfizer Inc. received preliminary court approval for a settlement in a shareholder derivative lawsuit.
- 2The lawsuit is titled 'In re Pfizer Inc. Shareholder Derivative Litigation'.
- 3The preliminary approval was granted by the U.S. District Court for the Southern District of New York.
- 4A final court approval hearing is scheduled for March 7, 2011.
- 5The terms of the proposed settlement are detailed in a separate notice filed as an exhibit.
- 6This filing indicates a potential resolution to ongoing litigation.
- 7Investors should track the final approval of the settlement.